Detalles de la búsqueda
1.
BID expression determines the apoptotic fate of cancer cells after abrogation of the spindle assembly checkpoint by AURKB or TTK inhibitors.
Mol Cancer
; 22(1): 110, 2023 07 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-37443114
2.
Targeting BCL2 Overcomes Resistance and Augments Response to Aurora Kinase B Inhibition by AZD2811 in Small Cell Lung Cancer.
Clin Cancer Res
; 29(16): 3237-3249, 2023 08 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-37289191
3.
A phase 1/2 study of the combination of acalabrutinib and vistusertib in patients with relapsed/refractory B-cell malignancies.
Leuk Lymphoma
; 62(11): 2625-2636, 2021 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-34269152
4.
AZD0364 Is a Potent and Selective ERK1/2 Inhibitor That Enhances Antitumor Activity in KRAS-Mutant Tumor Models when Combined with the MEK Inhibitor, Selumetinib.
Mol Cancer Ther
; 20(2): 238-249, 2021 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-33273059
5.
Discovery and Optimization of Pyrrolopyrimidine Inhibitors of Interleukin-1 Receptor Associated Kinase 4 (IRAK4) for the Treatment of Mutant MYD88L265P Diffuse Large B-Cell Lymphoma.
J Med Chem
; 60(24): 10071-10091, 2017 12 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-29172502
6.
Selective antagonism of the NPY Y5 receptor does not have a major effect on feeding in rats.
Diabetes
; 51(8): 2441-9, 2002 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-12145156
7.
Discovery and optimization of a series of carbazole ureas as NPY5 antagonists for the treatment of obesity.
J Med Chem
; 45(16): 3509-23, 2002 Aug 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-12139462
8.
Expanding medicinal chemistry space.
Drug Discov Today
; 18(5-6): 298-304, 2013 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-23117010
9.
Novel 4-anilinoquinazolines with C-6 carbon-linked side chains: synthesis and structure-activity relationship of a series of potent, orally active, EGF receptor tyrosine kinase inhibitors.
Bioorg Med Chem Lett
; 16(10): 2672-6, 2006 May 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-16516473
10.
Cyclin-dependent kinase 4 inhibitors as a treatment for cancer. Part 1: identification and optimisation of substituted 4,6-bis anilino pyrimidines.
Bioorg Med Chem Lett
; 13(18): 2955-60, 2003 Sep 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-12941311
11.
Cyclin-dependent kinase 4 inhibitors as a treatment for cancer. Part 2: identification and optimisation of substituted 2,4-bis anilino pyrimidines.
Bioorg Med Chem Lett
; 13(18): 2961-6, 2003 Sep 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-12941312
Resultados
1 -
11
de 11
1
Próxima >
>>